Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
24 Jul 2020  |  North America
Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies
With this research service, Frost & Sullivan’s Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapi...
05 May 2020  |  North America
Benchmarking Future Growth Potential
Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...
31 Jan 2020  |  North America
COVID-19 Pandemic will Drive New Digital-tech Adoption in Drug Discovery and Testing Services, and Federal Funding will Encourage Stronger Product Pipelines
The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...
27 Jan 2020  |  Global
Growth Opportunities—Contract Manufacturing and Outsourcing Opportunities in the In-vitro Diagnostics (IVD) Industry, 2019 to 2022
Consolidation and Innovative Business Models Will Accelerate IVD Outsourcing Growth
The increasing pressure for cost-driven development and regulatory and regional trends are inducing industry participants to adopt innovative integrated business models so as to align themselves as one-stop-shop solution providers as opposed to the traditional functional service providers, thereby, creating a mutually beneficial symbiotic relations...
10 Jan 2020  |  Asia Pacific
Expedited Regulatory Reviews, Accompanied by Surging Novel Drug Pipelines and a Realigned Distribution System will Propel the Chinese Pharma Industry
With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...
30 Dec 2019  |  Global
A Review of Novel Enzyme Technologies and Enzyme Applications in API Production, Therapeutics, Diagnosis, Medical Detergents, and Enzyme Expression Systems, Including Enzyme Manufacturing for Pharmaceuticals
The current study discusses the novel enzyme technologies for enzyme discovery and improvement such as directed mutagenesis, metagenomics, artificial intelligence and computational biology approaches and highthroughput technologies used for generation of enzyme variant libraries. Additionally, novel enzyme applications and potential applications in...
17 Dec 2019  |  Global
Microbiome-based Innovations Transforming the Personal Care Landscape
Skin microbiome industry has been rapidly evolving since the past few years and is likely to witness new innovations in the near future. Apart from emerging new start-ups in this area, several leading cosmetic and industry participants are likely to shift focus towards emerging microbiome-based beauty platforms.As the consumer focuses towards the...
02 Dec 2019  |  North America
Growth Opportunities in the Global Pharmaceutical Contract Manufacturing Organization Market (CMO), Forecast to 2024
Advancements in Continuous Manufacturing Technology, Necessary to Meet New Demand in the Orphan Drugs Segment and Personalized Medicine, Will Give a New Growth Vector to CMOs
Traditionally, CMOs have thrived by aggregating demand and delivering benefits of economies of scale. However, with the fading era of blockbuster drugs dispensed to large patient pools and shift to precision medicine, focus on niche indications, and increased R&D in biologics, pharma sponsors are increasingly turning to CMOs as strategic partners i...
27 Nov 2019  |  North America
Increased Technology Adoption in the Form of eClinical Solutions and Innovative Trial Designs is Expected to Transform the CRO Landscape
Increased technology adoption in the form of eClinical solutions and innovative trial designs is expected to transform the CRO landscape. Owing to a constantly changing pharmaceutical landscape, the industry is expected to witness a moderate 4% to 5% growth in the next 5 to 7 years, to surpass $1.5 trillion by 2025. In coordination with the indust...
06 Nov 2019  |  North America
Strategic Collaborations and Stakeholder Awareness Along with Clear Paths to Commercialization will Play a Key Role for Success in the Human Microbiome Market
Interest in the microbiome as a science and industry has exploded over the past decade. Innovations are happening across 3 significant categories for human health benefits: microbiome-based therapeutics, over-the-counter (OTC) dietary supplements, and self-diagnostics/screening. The OTC market is the largest because of the lack of precise regulatio...